Glucose-sensing transcription factor mondoa/chrebp as targets for type 2 diabetes: Opportunities and challenges

Ziyi Song, Hao Yang, Lei Zhou, Fajun Yang

Research output: Contribution to journalArticle

Abstract

The worldwide increase in type 2 diabetes (T2D) is becoming a major health concern, thus searching for novel preventive and therapeutic strategies has become urgent. In last decade, the paralogous transcription factors MondoA and carbohydrate response element-binding protein (ChREBP) have been revealed to be central mediators of glucose sensing in multiple metabolic organs. Under normal nutrient conditions, MondoA/ChREBP plays vital roles in maintaining glucose homeostasis. However, under chronic nutrient overload, the dysregulation of MondoA/ChREBP contributes to metabolic disorders, such as insulin resistance (IR) and T2D. In this review, we aim to provide an overview of recent advances in the understanding of MondoA/ChREBP and its roles in T2D development. Specifically, we will briefly summarize the functional similarities and differences between MondoA and ChREBP. Then, we will update the roles of MondoA/ChREBP in four T2D-associated metabolic organs (i.e., the skeletal muscle, liver, adipose tissue, and pancreas) in physiological and pathological conditions. Finally, we will discuss the opportunities and challenges of MondoA/ChREBP as drug targets for anti-diabetes. By doing so, we highlight the potential use of therapies targeting MondoA/ChREBP to counteract T2D and its complications.

Original languageEnglish (US)
Article number5132
JournalInternational Journal of Molecular Sciences
Volume20
Issue number20
DOIs
StatePublished - Oct 2 2019

Fingerprint

Transcription factors
carbohydrates
Response Elements
Carbohydrates
Medical problems
glucose
Type 2 Diabetes Mellitus
Glucose
Carrier Proteins
Transcription Factors
proteins
nutrients
organs
Nutrients
adipose tissues
homeostasis
pancreas
Food
skeletal muscle
insulin

Keywords

  • Adipose tissue
  • ChREBP
  • Glucose
  • Insulin resistance
  • Liver
  • Metabolism
  • MondoA
  • Pancreas
  • Skeletal muscle
  • Type 2 diabetes

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Glucose-sensing transcription factor mondoa/chrebp as targets for type 2 diabetes : Opportunities and challenges. / Song, Ziyi; Yang, Hao; Zhou, Lei; Yang, Fajun.

In: International Journal of Molecular Sciences, Vol. 20, No. 20, 5132, 02.10.2019.

Research output: Contribution to journalArticle

@article{ef9f0dbf312245069a364fb646d5ff03,
title = "Glucose-sensing transcription factor mondoa/chrebp as targets for type 2 diabetes: Opportunities and challenges",
abstract = "The worldwide increase in type 2 diabetes (T2D) is becoming a major health concern, thus searching for novel preventive and therapeutic strategies has become urgent. In last decade, the paralogous transcription factors MondoA and carbohydrate response element-binding protein (ChREBP) have been revealed to be central mediators of glucose sensing in multiple metabolic organs. Under normal nutrient conditions, MondoA/ChREBP plays vital roles in maintaining glucose homeostasis. However, under chronic nutrient overload, the dysregulation of MondoA/ChREBP contributes to metabolic disorders, such as insulin resistance (IR) and T2D. In this review, we aim to provide an overview of recent advances in the understanding of MondoA/ChREBP and its roles in T2D development. Specifically, we will briefly summarize the functional similarities and differences between MondoA and ChREBP. Then, we will update the roles of MondoA/ChREBP in four T2D-associated metabolic organs (i.e., the skeletal muscle, liver, adipose tissue, and pancreas) in physiological and pathological conditions. Finally, we will discuss the opportunities and challenges of MondoA/ChREBP as drug targets for anti-diabetes. By doing so, we highlight the potential use of therapies targeting MondoA/ChREBP to counteract T2D and its complications.",
keywords = "Adipose tissue, ChREBP, Glucose, Insulin resistance, Liver, Metabolism, MondoA, Pancreas, Skeletal muscle, Type 2 diabetes",
author = "Ziyi Song and Hao Yang and Lei Zhou and Fajun Yang",
year = "2019",
month = "10",
day = "2",
doi = "10.3390/ijms20205132",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "20",

}

TY - JOUR

T1 - Glucose-sensing transcription factor mondoa/chrebp as targets for type 2 diabetes

T2 - Opportunities and challenges

AU - Song, Ziyi

AU - Yang, Hao

AU - Zhou, Lei

AU - Yang, Fajun

PY - 2019/10/2

Y1 - 2019/10/2

N2 - The worldwide increase in type 2 diabetes (T2D) is becoming a major health concern, thus searching for novel preventive and therapeutic strategies has become urgent. In last decade, the paralogous transcription factors MondoA and carbohydrate response element-binding protein (ChREBP) have been revealed to be central mediators of glucose sensing in multiple metabolic organs. Under normal nutrient conditions, MondoA/ChREBP plays vital roles in maintaining glucose homeostasis. However, under chronic nutrient overload, the dysregulation of MondoA/ChREBP contributes to metabolic disorders, such as insulin resistance (IR) and T2D. In this review, we aim to provide an overview of recent advances in the understanding of MondoA/ChREBP and its roles in T2D development. Specifically, we will briefly summarize the functional similarities and differences between MondoA and ChREBP. Then, we will update the roles of MondoA/ChREBP in four T2D-associated metabolic organs (i.e., the skeletal muscle, liver, adipose tissue, and pancreas) in physiological and pathological conditions. Finally, we will discuss the opportunities and challenges of MondoA/ChREBP as drug targets for anti-diabetes. By doing so, we highlight the potential use of therapies targeting MondoA/ChREBP to counteract T2D and its complications.

AB - The worldwide increase in type 2 diabetes (T2D) is becoming a major health concern, thus searching for novel preventive and therapeutic strategies has become urgent. In last decade, the paralogous transcription factors MondoA and carbohydrate response element-binding protein (ChREBP) have been revealed to be central mediators of glucose sensing in multiple metabolic organs. Under normal nutrient conditions, MondoA/ChREBP plays vital roles in maintaining glucose homeostasis. However, under chronic nutrient overload, the dysregulation of MondoA/ChREBP contributes to metabolic disorders, such as insulin resistance (IR) and T2D. In this review, we aim to provide an overview of recent advances in the understanding of MondoA/ChREBP and its roles in T2D development. Specifically, we will briefly summarize the functional similarities and differences between MondoA and ChREBP. Then, we will update the roles of MondoA/ChREBP in four T2D-associated metabolic organs (i.e., the skeletal muscle, liver, adipose tissue, and pancreas) in physiological and pathological conditions. Finally, we will discuss the opportunities and challenges of MondoA/ChREBP as drug targets for anti-diabetes. By doing so, we highlight the potential use of therapies targeting MondoA/ChREBP to counteract T2D and its complications.

KW - Adipose tissue

KW - ChREBP

KW - Glucose

KW - Insulin resistance

KW - Liver

KW - Metabolism

KW - MondoA

KW - Pancreas

KW - Skeletal muscle

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85073609281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073609281&partnerID=8YFLogxK

U2 - 10.3390/ijms20205132

DO - 10.3390/ijms20205132

M3 - Article

C2 - 31623194

AN - SCOPUS:85073609281

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 20

M1 - 5132

ER -